...
首页> 外文期刊>HIV Research & Clinical Practice. >Correlation between plasma glucose and hemoglobin A1c in HIV-infected individuals receiving zidovudine and non-zidovudine containing antiretroviral therapy regimens
【24h】

Correlation between plasma glucose and hemoglobin A1c in HIV-infected individuals receiving zidovudine and non-zidovudine containing antiretroviral therapy regimens

机译:血浆葡萄糖和血红蛋白A1c之间的相关性在接受齐多夫丁和非Zidovudine的艾滋病毒感染的个体中

获取原文
获取原文并翻译 | 示例

摘要

abstract_textpBackground: Hemoglobin A1c (HbA1c) has been used for the diagnosis of diabetes and glycemic monitoring. However, using HbA1c for glycemia estimation has some fallacies in anemic persons. Zidovudine (AZT) treatment is associated with anemia and/or increased mean corpuscular volume (MCV). Objective: This study aimed to compare the correlation between HbA1c and plasma glucose in HIV-infected individuals who were receiving AZT and non-AZT containing regimens. Methods: A cross-sectional study was conducted in 150 HIV-infected individuals. We evaluated the correlation of paired fasting plasma glucose (FPG), random plasma glucose (RPG), mean plasma glucose (MPG) and HbA1c values by using Pearson correlation. Multivariate linear regression was used to determine the associated factors of HbA1c. Results: The mean age was 49.0 +/- 10.5 years, and 60.0% were male. Thirteen patients (8.7%) had diabetes and 14 patients (9.3%) had anemia. There were significant correlations between HbA1c and plasma glucose (FPG, RPG, and MPG; p 0.05, all). The correlation between HbA1c and MPG in patients receiving AZT [HbA1c = 3.18 + 0.02MPG; R-2=0.44] and not receiving AZT [HbA1c = 3.76 + 0.02MPG; R-2=0.43] indicated that HbA1c in patients receiving AZT was 0.58% underestimated. Multivariate linear regression analysis showed that hematocrit [beta 0.192; 95% confidence interval (CI) 0.003, 0.690; p = 0.032] and MCV [beta -0.195; 95% CI -0.326, -0.002; p = 0.047] were associated with HbA1c levels. Conclusions: HbA1c underestimates glycemia in HIV-infected individuals receiving AZT containing regimens. Factors associated with decreased HbA1c levels in HIV-infected individuals included decreased hematocrit and increased MCV. In HIV-infected individuals receiving AZT, using HbA1c for diabetes diagnosis or glycemia monitoring should be cautiously interpreted./p/abstract_text
机译:& Abstract_text&& p&背景:血红蛋白A1C(HBA1C)已用于诊断糖尿病和血糖监测。但是,使用HBA1C进行血糖估计有一些谬误。 Zidovudine(AZT)治疗与贫血和/或平均红细胞体积(MCV)有关。目的:这项研究旨在比较接受AZT和非AZT含有方案的HBA1C与血浆葡萄糖之间的相关性。方法:在150个HIV感染的个体中进行了一项横断面研究。我们通过使用Pearson相关性评估了配对的空腹血浆葡萄糖(FPG),随机等离子体葡萄糖(RPG),平均等离子体葡萄糖(MPG)和HBA1C值的相关性。多元线性回归用于确定HBA1C的相关因素。结果:平均年龄为49.0 +/- 10.5岁,男性为60.0%。 13例患者(8.7%)患有糖尿病,14例患者(9.3%)患有贫血。 HBA1C和血浆葡萄糖(FPG,RPG和MPG; P< 0.05)之间存在显着相关性。接受AZT的患者HBA1C和MPG之间的相关性[HBA1C = 3.18 + 0.02MPG; R-2 = 0.44],并且不接收AZT [HBA1C = 3.76 + 0.02MPG; R-2 = 0.43]表示接受AZT的患者的HBA1C被低估了0.58%。多元线性回归分析表明血细胞比容[β0.192; 95%置信区间(CI)0.003,0.690; p = 0.032]和mcv [beta -0.195; 95%CI -0.326,-0.002; p = 0.047]与HBA1C水平有关。结论:HBA1C低估了接受含有AZT方案的HIV感染的个体中的血糖。与HIV感染的个体中HBA1C水平降低相关的因素包括血细胞比容降低和MCV增加。在接受AZT的HIV感染者中,应谨慎解释使用HBA1C进行糖尿病诊断或血糖监测。

著录项

获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号